FDA Brief

Warning letters Drugs

FDA warning letter to

Velocity Pharma LLC

High riskIssued Jul 17, 2024Posted Aug 6, 2024Center for Drug Evaluation and Research (CDER)

Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.

What happened

FDA inspected Velocity Pharma’s Farmingdale, NY drug facility from November 3 to December 14, 2023, after an inspection at contract manufacturer Kilitch Healthcare India Limited revealed violative conditions. FDA found that Velocity used Kilitch and another contract manufacturer to make ophthalmic drugs but lacked adequate procedures to ensure quality and adequate supplier qualification, and its distribution records were missing addresses, batch numbers, and quantities shipped. FDA also said Velocity delayed action to remove adulterated products—drugs not meeting legal quality and safety standards—including its own-label eye drops after FDA notified it.

What FDA found

  1. Velocity lacked adequate procedures to ensure all ophthalmic drug products made for it met appropriate quality attributes, as required by current good manufacturing practice (CGMP).

    21 CFR Parts 210 and 211
  2. Velocity lacked adequate supplier qualification procedures to ensure drugs from Kilitch and another contract manufacturer were made in compliance with CGMP before U.S. distribution.

    21 CFR Parts 210 and 211
  3. Velocity received and delivered adulterated ophthalmic drugs into interstate commerce.

    FD&C Act sections 301(a) and 301(c), 21 U.S.C. 331(a) and 331(c)
  4. Velocity’s distribution records were missing addresses, batch numbers, and quantities shipped from its facility.

  5. After FDA told Velocity that Kilitch’s products were adulterated, Velocity did not act to remove them from the market, including its own-label products.

  6. The ophthalmic products were adulterated because they were made under insanitary conditions and with CGMP violations at contract manufacturers.

    FD&C Act section 501(a)(2)(A) and (B), 21 U.S.C. 351(a)(2)(A) and (B)

What FDA wants

FDA asks Velocity to respond in writing within 15 working days with a detailed plan to ensure it does not receive or deliver adulterated drugs, including a full evaluation of its supplier and contract-manufacturer qualification program, periodic audits, and evaluation of current suppliers and contract manufacturers. Correct violations promptly; if not completed in 15 working days, give reasons and a schedule.

Who should pay attention

  • distributors and retailers of ophthalmic drugs
  • brands that use contract manufacturers for sterile drugs
  • companies that rely on supplier qualification and contract-manufacturer audits

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk